Sphere FluidicsDale Levitzke has been appointed as CEO of Sphere Fluidics. He follows CEO and co-founder Dr Frank F. Craig, who announced his retirement after 14 years leading the company.
Swiss antibody specialist Memo Therapeutics AG has added CHF20m to its Series C financing, bringing the total amount raised in the funding round to CHF 45 million.
More than 900 experts from clusters and the EU Commission discussed at the sold-out 9th European Cluster Conference what cluster policy is needed to make Europe a world leader in prioritised technology fields such as the green and digital transitions and biotechnology.
Danish CDMO 21st.BIO A/S has unveiled a new pilot plant facility to accelerate scaling of biotech processes ranging from food and beverages, agriculture, biomaterials, and biopharma.
Single-use bioreactor technology offers a set of benefits compared to common glass or stainless-steel vessels, including reduced downtime between runs, minimal cleaning effort, or decreased cross-contamination risk. In that regard, BioBLU® Single-Use Bioreactors combine the benefits of single-use bioreactor technology with the reliable performance of conventional glass or stainless-steel bioreactors. Furthermore, using them together with a powerful bioprocess controller like the BioFlo® 320 enables precise cell culture parameter control and seamless process transition to up to 40 L of working volume.
Flagging of CAR-T cells with the B7H6 protein weakened the response to human leukaemia in models as it marks them for NK cell attack, German researchers report.
Belgian AgTech specialist Biotalys BV an Agricultural Technology (AgTech) company has initiated field trials for BioFun-6, the company’s second llama-antibody-mimicking biofungicide program.
Global contract research organization honored as top outsourcing partner, earning high marks in several categories from Industry Standard Research.
Oslo-based Calluna Pharma appoints Margrethe Sørgaard as Senior Vice President of Clinical Operations and Pharmacovigilance.
AI specialist WhiteLab Genomics, the Vision Institute, and IT expert ADLIN Science, have entered into a strategic partnership aimed at developing new AAV vectors targetting retinal dystrophies.